Evidence map›Paper›PMID 42795351›Full record

ReviewLife (Basel, Switzerland)2026

Genetic Variants Associated with Response to GLP-1 Receptor Agonists in Diabetes and Obesity.

Mónica T Fernandes, Joana C Dias, Margarida Espírito-Santo, Maria Dulce Estêvão, Ana Luísa De Sousa-Coelho

Abstract readReview
In one paragraph

Review in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mónica T FernandesFaculdade de Medicina e Ciências Biomédicas (FMCB), Universidade do Algarve, 8005-139 Faro, Portugal.ORCID 0000-0002-1206-1367
Joana C DiasFaculdade de Ciências e Tecnologia (FCT), Universidade do Algarve, 8005-139 Faro, Portugal.
Margarida Espírito-SantoAlgarve Biomedical Center Research Institute (ABC-Ri), Universidade do Algarve, 8005-139 Faro, Portugal.ORCID 0000-0002-2200-0015
Maria Dulce EstêvãoAlgarve Biomedical Center Research Institute (ABC-Ri), Universidade do Algarve, 8005-139 Faro, Portugal.ORCID 0000-0002-7151-8363
Ana Luísa De Sousa-CoelhoAlgarve Biomedical Center Research Institute (ABC-Ri), Universidade do Algarve, 8005-139 Faro, Portugal.ORCID 0000-0002-8451-4302

Funding

Fundação para a Ciência e Tecnologia 10.54499/UID/06210/2025
6 · The paper itself

Abstract

Genetic variation may contribute to interindividual differences in the efficacy and tolerability of glucagon-like peptide-1 receptor agonists (GLP-1RAs), although the available evidence remains limited. Certain gene variants may underlie variability in glycemic control and weight loss outcomes among patients treated with GLP-1RAs for diabetes and/or obesity. A better understanding of these genetic variations could have significant implications for the development of personalized medicine, contributing to predicting patient responses to GLP-1RAs. Within this review, we collected and synthesized information from different studies about genetic variants that have been reported to be associated with altered therapeutic response to GLP-1RAs, mostly in

Indexed as

diabetesgenetic variantsGLP-1 receptor agonist (GLP-1RA)GLP-1 receptor (GLP-1R, GLP1R)glucagon like peptide 1 (GLP-1, GLP1) analogsincretinsobesitypolymorphisms

Identifiers

PMID42795351
PMCPMC13608023

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.